Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound
The Prostate · 2024
DOI: 10.1002/pros.24785 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Fabian Falkenbach und 9 weiteren Autor:innen. Beteiligte Einrichtung: Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging, Prostate. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
To explore the detection rates of clinically significant prostate cancer (csPCa; ISUP ≥2) in patients with a single MRI lesion that is visible or invisible on transrectal ultrasound (TRUS) during biopsy.
Methods
Retrospective analyses of patients who underwent targeted and systematic biopsy of the prostate for one MRI‐visible lesion (PI‐RADS score ≥ 3) between 2017 and 2022. TRUS‐visibility, PI‐RADS score, and clinical parameters were recorded prospectively. Univariable and multivariable logistic regression models were used to identify predictors of csPCa.
Results
277 consecutive patients with one MRI‐visible lesion were identified. A correlating lesion on TRUS was present in 147/277 (53%). The median age, PSA level, and prostate volume were 68.0 years (IQR: 62.0–73.0), 7.3 ng/ml (IQR: 5.4–10.8) and 45.0 cc (IQR: 32.0–68.0), respectively. Baseline parameters were not significantly different between the two groups. CsPCa was detected in 59/130 (45%) without and in 102/147 (69%) patients with a corresponding TRUS lesion. In multivariable logistic regression analysis predicting csPCa, TRUS‐visibility (OR: 2.13, CI: 1.14–4.03, p = 0.02) and PI‐RADS score (PI‐RADS 4: OR: 7.28, CI: 3.33–17.19; PI‐RADS 5: OR: 13.39, CI: 5.27–36.83, p < 0.001) achieved independent predictor status.
Conclusions
Bimodal‐visible lesions more often harbored csPCa and were easier to target. TRUS‐visibility of MRI lesions is an independent predictor of csPCa. Therefore, education in both modalities is essential. Despite MRI, the ultrasound should still be diligently examined.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
- Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
ORCID-Profile: Fabian Falkenbach, Mykyta Kachanov
Zitieren
APA
Falkenbach, F., Ahmad-Sterkau, F., Kachanov, M., Beyersdorff, D., Koehler, D., Ambrosini, F., Ortner, G., Maurer, T., Graefen, M., & Budäus, L. (2024). Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound. The Prostate. https://doi.org/10.1002/pros.24785
Vancouver
Falkenbach F, Ahmad-Sterkau F, Kachanov M, Beyersdorff D, Koehler D, Ambrosini F, et al. Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound. The Prostate. 2024. doi:10.1002/pros.24785
BibTeX
@article{Falkenbach2024,
author = {Falkenbach, Fabian and Ahmad-Sterkau, Fatima and Kachanov, Mykyta and Beyersdorff, Dirk and Koehler, Daniel and Ambrosini, Francesca and Ortner, Gernot and Maurer, Tobias and Graefen, Markus and Budäus, Lars},
title = {Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound},
journal = {The Prostate},
year = {2024},
doi = {10.1002/pros.24785}
}
EUVIMED